Augmentation of EPR effect and therapeutic effect of nanomedicine by inhibiting off-targeting delivery

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K07743
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Sojo University
• Principal Investigator: Fang Jun 崇城大学, 薬学部, 准教授 (20412736)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: EPR効果 / ナノメディシン / off-targetデリバリー / イントラリピッド / 腫瘍血流

Outline of Final Research Achievements

In this study, we investigated the usefulness of the clinically used lipid emulsion, Intralipid, which has a function of suppressing the reticuloendothelial system, in suppressing the off-target delivery of anticancer nanomedicines. Intralipid pretreatment led to a significant reduction in liver accumulation of various anticancer nanomedicines, an increase in blood half-life, improvement in tumor blood flow, and a significant increase in tumor delivery. As a result, the combination of Intralipid and nanomedicines significantly improved the therapeutic effect of anticancer nanomedicines. These results suggest that the combination therapy of Intralipid and nanomedicines could be a new anticancer strategy with potential clinical applications.

Free Research Field

抗がんナノメディシン、DDS、癌治療、EPR効果

Academic Significance and Societal Importance of the Research Achievements

本研究の成果により、静脈栄養剤として臨床で広く応用されるIntralipidを用いることで、ナノメディシンのoff-targetデリバリーの抑制による副作用の少ないEPR効果の増強法を確立できると考えられます。その結果、ナノメディシンのより効率的かつこれまで以上に優れた抗がん治療効果が得られると信じています。つまり、本研究の成果はがんの効率的な治療に繋がり、医療費の削減ならびにがん患者のQOL向上に寄与するものと強く期待されています。